Erythropoietin

Warning: Undefined array key "S1" in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Erythropoietin.php on line 2
Erythropoietin

LE WE PMID CA

Erythropoietin

841

Erythropoietin

Anemia (Renal)

Autoantibodies Anti Erythropoietein

CNS (Stroke BASKET)

Erythropoiesis stimulating agents

Erythropoietin

Heart (Coronary heart disease BASKET)

Hemopoiesis (BASKET)

HIF1alpha und HIF1 (BASKET)

Kidney (Failure acute)

Kidney (REPOS cells)

Myelodysplastic syndrome

Neuroprotective agents

Podocalyxin like1

Sepsis

Tribbles3

Wound healing

2008 1	Erythropoietin-mediated tissue protection: reducing collateral damage from the primary injury response. [19017170] J Intern Med 264(5): 405-32 (2008)
2002 2	Hematopoietic factor erythropoietin fosters neuroprotection through novel signal transduction cascades. [11973422] J Cereb Blood Flow Metab 22(5): 503-14 (2002)
2010 3	A systematic review and meta-analysis of erythropoietin in experimental stroke. [20040929] J Cereb Blood Flow Metab 30(5): 961-8 (2010)
2007 4	Nanomedicines in the treatment of anemia in renal disease: focus on CERA (Continuous Erythropoietin Receptor Activator). [17722510] Int J Nanomedicine 2(1): 33-8 (2007)
2009 5	Arterial hypertension induced by erythropoietin and erythropoiesis-stimulating agents (ESA). [19218474] Clin J Am Soc Nephrol 4(2): 470-80 (2009)
1991 6	Analysis of physician questions in an ambulatory care setting. [1807782] Proc Annu Symp Comput Appl Med Care -(-): 995-9 (1991)
2007 7	Mechanism of increased mortality risk with erythropoietin treatment to higher hemoglobin targets. [17942772] Clin J Am Soc Nephrol 2(6): 1274-82 (2007)
2008 8	Erythropoietins in cancer patients: ESMO recommendations for use. [18456746] Ann Oncol 19 Suppl 2(-): ii113-5 (2008)
2007 9	Expression and function of erythropoietin receptors in tumors: implications for the use of erythropoiesis-stimulating agents in cancer patients. [17582631] Cancer 110(3): 477-88 (2007)
2006 10	Are there clinical benefits with early erythropoietic intervention for chemotherapy-induced anemia? A systematic review. [16331597] Cancer 106(1): 223-33 (2006)
2005 11	Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. [15812074] J Natl Cancer Inst 97(7): 489-98 (2005)
2009 12	Is nephrology more at ease than oncology with erythropoiesis-stimulating agents? Treatment guidelines and an update on benefits and risks. [19762517] Oncologist 14 Suppl 1(-): 57-62 (2009)
2009 13	Anemia management in oncology and hematology. [19762516] Oncologist 14 Suppl 1(-): 43-56 (2009)
2009 14	Examining the involvement of erythropoiesis-stimulating agents in tumor proliferation (erythropoietin receptors, receptor binding, signal transduction), angiogenesis, and venous thromboembolic events. [19762515] Oncologist 14 Suppl 1(-): 34-42 (2009)
2009 15	Update on anemia management in nephrology, including current guidelines on the use of erythropoiesis-stimulating agents and implications of the introduction of "biosimilars". [19762513] Oncologist 14 Suppl 1(-): 16-21 (2009)
2009 16	Update on erythropoiesis-stimulating agents and clinical trials in oncology. [19762512] Oncologist 14 Suppl 1(-): 6-15 (2009)
2009 17	An update on twenty years of anemia management with erythropoiesis-stimulating agents in nephrology and oncology/hematology. [19762511] Oncologist 14 Suppl 1(-): 1-5 (2009)
2008 18	The role of recombinant erythropoietin in childhood cancer. [18305061] Oncologist 13(2): 157-66 (2008)
2008 19	Venous thromboembolic events and erythropoiesis-stimulating agents: an update. [18458119] Oncologist 13 Suppl 3(-): 11-5 (2008)
2008 20	Safety update on erythropoiesis-stimulating agents: trials within and outside the accepted indications. [18458118] Oncologist 13 Suppl 3(-): 4-10 (2008)
2008 21	Editorial: anemia management with erythropoiesis-stimulating agents: a risk-benefit update. [18458117] Oncologist 13 Suppl 3(-): 1-3 (2008)
2007 22	Efficacy and safety of erythropoiesis-stimulating proteins in myelodysplastic syndrome: a systematic review and meta-analysis. [17962620] Oncologist 12(10): 1264-73 (2007)
2004 23	Apoptotic mechanisms in the control of erythropoiesis. [15208642] Leukemia 18(7): 1176-99 (2004)
2003 24	Erythropoietin: physiology and pharmacology update. [12524467] Exp Biol Med (Maywood) 228(1): 1-14 (2003)
2002 25	EPO's alter ego: erythropoietin has multiple actions. [12456956] Stem Cells 20(6): 485-92 (2002)
1993 26	Signal transduction in the erythropoietin receptor system. [8241949] Stem Cells 11(5): 381-92 (1993)
2008 27	Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update. [17954703] Blood 111(1): 25-41 (2008)
1991 28	Erythropoietin. [1991159] Blood 77(3): 419-34 (1991)
2008 29	Pure red cell aplasia induced by erythropoiesis-stimulating agents. [18178785] Clin J Am Soc Nephrol 3(1): 193-9 (2008)
2008 30	Novel erythropoiesis-stimulating agents: a new era in anemia management. [18077782] Clin J Am Soc Nephrol 3(1): 200-7 (2008)
1998 31	Biology of erythropoietin. [9793257] Haematologica 83(8): 724-32 (1998)
2001 32	Erythropoietin: a paradigm for the development of practice guidelines. [11722976] Hematology Am Soc Hematol Educ Program -(-): 10-30 (2001)
2004 33	Molecular biology of erythropoietin. [15468961] Intern Med 43(8): 649-59 (2004)
2003 34	Pleiotropic functions of erythropoietin. [12636232] Intern Med 42(2): 142-9 (2003)
2006 35	Erythropoietin in clinical practice: current use, effect on survival, and future directions. [17125118] Isr Med Assoc J 8(10): 703-6 (2006)
2002 36	Erythropoietin and its receptor: signaling and clinical manifestations. [12489509] Isr Med Assoc J 4(11): 1072-6 (2002)
2008 37	Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. [18314434] JAMA 299(8): 914-24 (2008)
2007 38	Use of erythropoiesis-stimulating agents in patients with anemia of chronic kidney disease: overcoming the pharmacological and pharmacoeconomic limitations of existing therapies. [17976358] Mayo Clin Proc 82(11): 1371-80 (2007)
2007 39	Recombinant EPO production--points the nephrologist should know. [17595190] Nephrol Dial Transplant 22(10): 2749-53 (2007)
1999 40	The molecular biology of erythropoietin. [10334664] Nephrol Dial Transplant 14 Suppl 2(-): 22-8 (1999)
2003 41	Recombinant erythropoietin in clinical practice. [12897214] Postgrad Med J 79(933): 367-76 (2003)
1991 42	The use of erythropoietin in renal failure. [2057440] Postgrad Med J 67(783): 9-15 (1991)
1992 43	Erythropoietin therapy in patients with chronic renal failure. [1441466] West J Med 157(2): 154-7 (1992)
2009 44	Use of agents stimulating erythropoiesis in digestive diseases. [19787831] World J Gastroenterol 15(37): 4675-85 (2009)
1997 45	Erythropoietin in the pathogenesis and treatment of the anemia of chronic renal failure. [9067892] Kidney Int 51(3): 622-30 (1997)
1996 46	Erythropoietin in chronic renal failure. [8887302] Kidney Int 50(4): 1373-91 (1996)
1993 47	Molecular biology of erythropoietin. [8258966] Kidney Int 44(4): 887-904 (1993)
1989 48	The anemia of chronic renal failure: pathophysiology and the effects of recombinant erythropoietin. [2651751] Kidney Int 35(1): 134-48 (1989)
2009 49	Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis. [19407261] CMAJ 180(11): E62-71 (2009)
2007 50	Erythropoietin-receptor agonists in critically ill patients: a meta-analysis of randomized controlled trials. [17823140] CMAJ 177(7): 725-34 (2007)
2004 51	Erythropoiesis-stimulating agents and antibody-mediated pure red-cell aplasia: here are we now and where do we go from here? [14736947] Nephrol Dial Transplant 19(2): 288-93 (2004)
2010 52	Nonhematopoietic variants of erythropoietin in ischemic stroke: need for step-wise proof-of-concept studies. [21103797] ScientificWorldJournal 10(-): 2285-7 (2010)
2010 53	Non-erythroid effects of erythropoietin. [21037325] Haematologica 95(11): 1803-5 (2010)
2003 54	New insights into erythropoietin and epoetin alfa: mechanisms of action, target tissues, and clinical applications. [14671225] Oncologist 8 Suppl 3(-): 18-29 (2003)
2010 55	Bench to bedside: A role for erythropoietin in sepsis. [20727227] Crit Care 14(4): 227 (2010)
2010 56	Hypoxic regulation of erythropoiesis and iron metabolism. [20444740] Am J Physiol Renal Physiol 299(1): F1-13 (2010)
2010 57	Regulated oxygen sensing by protein hydroxylation in renal erythropoietin-producing cells. [20219824] Am J Physiol Renal Physiol 298(6): F1287-96 (2010)
2011 58	Beyond hematopoietic targets: the role of erythropoietin in diabetic wound healing. [21657844] Biomark Med 5(3): 365-7 (2011)
2010 59	Erythropoietin receptor response circuits. [20173635] Curr Opin Hematol 17(3): 169-76 (2010)
2011 60	Erythropoietin in the intensive care unit: beyond treatment of anemia. [21943500] Ann Intensive Care 1(-): 40 (2011)
2011 61	Erythropoietin (EPO) in acute kidney injury. [21906325] Ann Intensive Care 1(1): 3 (2011)
2010 62	Erythropoietin for infants with hypoxic-ischemic encephalopathy. [20090525] Curr Opin Pediatr 22(2): 139-45 (2010)
2007 63	Erythropoietin treatment for ischemic cardiomyopathy: anemia correction and myocardial protection. [18301786] Timely Top Med Cardiovasc Dis 11(-): E33 (2007)
2008 64	Recent trends in erythropoietin-mediated neuroprotection. [17936539] Int J Dev Neurosci 26(1): 103-11 (2008)
2008 65	Erythropoietin: elucidating new cellular targets that broaden therapeutic strategies. [18396368] Prog Neurobiol 85(2): 194-213 (2008)
2011 66	Twist and shout: one decade of meta-analyses of erythropoiesis-stimulating agents in cancer patients. [21150188] Acta Haematol 125(1-2): 55-67 (2011)
PMC 67	An emerging need for developing new models for myocardial infarction as a chronic complex disease: lessons learnt from animal vs. human studies on cardioprotective effects of Erythropoietin in reperfused myocardium. [24575050] Front Physiol 5():44 (2014)

Downloaded from http://www.kidney.de - The Database of Free Medical Reviews - The Metatextbook of Medicine - Ossip Groth

All Medline data shown were primarily retrieved from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Fatal error: Uncaught Error: Call to undefined function mysql_connect() in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Erythropoietin.php:92 Stack trace: #0 {main} thrown in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Erythropoietin.php on line 92